How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/breast-cancer-with-a-pik3ca-mutation.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Breast cancer with a PIK3CA mutation — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Breast cancer with a PIK3CA mutation (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Breast cancer with a PIK3CA mutation, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
PF-07850327, ARV-471, vepdegestrant	pf-07850327-arv-471-vepdegestrant	Pfizer	Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)	Estrogen Receptor (ER)

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 1 drug in Breast cancer with a PIK3CA mutation

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Breast cancer with a PIK3CA mutation:

Cite this brief

Drug Landscape (2026). Breast cancer with a PIK3CA mutation — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/breast-cancer-with-a-pik3ca-mutation. Accessed 2026-06-10.

Breast cancer with a PIK3CA mutation full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing